Akero Therapeutics Inc. (NASDAQ: AKRO) is one of the best mid cap pharma stocks to buy. On July 16, AstraZeneca announced ...

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

One chemistry tweak made mRNA vaccines dramatically safer and more effective—unlocking new potential for fighting disease.

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Learn how ATTR-CM is treated with medications that slow down the condition's progression and other therapies that reduce ...

In this video, Shahzad Raza, MD, discusses safety and efficacy data from Nexicart-2, which studied the use of chimeric antigen receptor T-cell therapy in relapsed or refractory light chain amyloidosis ...

In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has already been approved in ...

The Call For Contributors to this year’s Comics Forum 2025, taking place at Leeds Art Gallery and Central Library over ...

There is decreased risk of all-cause and CV mortality in patients with transthyretin amyloidosis with cardiomyopathy treated with vutrisiran.

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare disease called ...